Company profile: CoRegen
1.1 - Company Overview
Company description
- Provider of SRC-3 and Treg-focused therapies: SRC-3 KO Treg Therapy that engineers Treg cells to infiltrate and destroy tumors; an SRC-3 small molecule inhibitor that blocks transcriptional activity to inhibit cancer growth and boost immune response; an SRC-3 small molecule enhancer to reduce inflammation and improve tissue repair in myocardial infarction and stroke; and Treg engineering.
Products and services
- SRC-3 KO Treg Therapy: Genetically engineered Treg cells modify the SRC-3 gene to target and eliminate cancer cells, enhancing immune infiltration and tumor destruction with precise, tumor-directed activity
- SRC-3 Small Molecule Enhancer: Small-molecule agent stimulates target genes to treat myocardial infarction and stroke by reducing inflammation and improving tissue repair, enabling regenerative responses in damaged tissues
- SRC-3 Small Molecule Inhibitor: Small-molecule agent blocks the transcriptional activity of SRC-3, inhibiting cancer cell growth and promoting immune system response
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CoRegen
Kronos Bio
HQ: United States
Website
- Description: Provider of oncology therapies that modulate historically undruggable cancer targets. Pipeline includes KB-0742, a CDK9 inhibitor in phase 1/2 for MYC-dependent tumors, and KB-9558 targeting the p300 KAT domain for multiple myeloma. Offers a Small Molecule Microarray screening platform for transcription factor binding assays and a discovery collaboration with Genentech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kronos Bio company profile →
Proteovant Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions utilizing protein degradation research to develop medicines for diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proteovant Therapeutics company profile →
MabVax Therapeutics
HQ: United States
Website
- Description: Provider of proprietary anti-cancer immunotherapies as a biopharmaceutical company focused on their commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MabVax Therapeutics company profile →
LungLife AI
HQ: United States
Website
- Description: Provider of molecular diagnostics for early cancer detection and treatment, offering the LungLB® Test, a blood-based diagnostic that provides additional information to clinicians evaluating indeterminate lung nodules, potentially reducing unnecessary invasive procedures and delays in treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LungLife AI company profile →
Janux Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapies that activate T cells in the tumor microenvironment while sparing healthy tissue, including PSMA-TRACTr (JANX007) for metastatic castration-resistant prostate cancer and EGFR-TRACTr (JANX008) in Phase 1 for carcinomas, built on proprietary TRACTr and TRACIr bispecific platforms; partnered with Merck to develop next-generation T cell engager immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janux Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CoRegen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CoRegen
2.2 - Growth funds investing in similar companies to CoRegen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CoRegen
4.2 - Public trading comparable groups for CoRegen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →